Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).
The company’s lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models.
In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers.
The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Zachary Hornby |
Contact Details
Address: 10955 Alexandria Way, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 766 9912 |
| Website | boundlessbio.com |
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782303 |
| CUSIP Number | 10170A100 |
| ISIN Number | US10170A1007 |
| Employer ID | 83-0751369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zachary Hornby | Chief Executive Officer, President and Director |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
| David Hinkle | Senior Vice President of Finance, Controller and Corporate Treasurer |
| Jessica Oien J.D. | Chief Legal Officer and Corporate Secretary |
| Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery |
| Meredith Wesley | Senior Vice President of Talent and Culture |
| Dr. Peter Krein Ph.D. | Senior Vice President of Precision Medicine |
| Amy Berkley Ph.D. | Senior Vice President of Program Team |
| Sara Weymer | Senior Vice President of Clinical Operations |
| Dr. James L. Freddo M.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 8, 2025 | UPLOAD | Filing |
| Apr 1, 2025 | 8-K | Current Report |
| Apr 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2025 | 10-K | Annual Report |